MiNK Therapeutics
Tracked across 3 events · 22 articles · First seen Feb 04, 2026 · Last active Apr 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
MiNK Therapeutics announced new translational data supporting the role of iNKT cells in idiopathic pulmonary fibrosis (IPF), which strengthens the rationale for their iNKT cell replenishment strategies. This expands MiNK Therapeutics' platform relevance into chronic fibrotic and senescence-associated indications, complementing ongoing development programs.
Feb 04, 2026 · 8 articles
Tech
MiNK Therapeutics announced positive data from its Phase II trial for agenT-797 in combination with botensilimab and balstilimab for gastroesophageal cancer. This suggests potential for their lead candidate and could lead to further development and partnerships.
Apr 17, 2026 · 7 articles
100
MiNK Therapeutics announced positive Phase II clinical trial dataMiNK Therapeutics...
Jennifer Buell
President and CEO
↔
MiNK Therapeutics
Jennifer Buell is the President and CEO of MiNK Therapeutics.
Terese Hammond
Head of Pulmonary and Inflammatory Diseases
↔
MiNK Therapeutics
Terese Hammond is the Head of Pulmonary and Inflammatory Diseases at MiNK Therap
Memorial Sloan Kettering Cancer Center
trial investigator
↔
MiNK Therapeutics
Memorial Sloan Kettering Cancer Center conducted the Phase II trial for MiNK The
NEWSDESK
Track MiNK Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard